Biotech investments
driven by the accurate prediction of clinical trial success rates
We thrive to accurately predict clinical trial results and the resulting changes in share price of publicly traded biotechnology companies. Wrapped in a proprietary investment strategy, we aim to generate returns for investors with low market correlation, while at the same time advancing scientific breakthroughs for patients.
We are specialists in fundamental analysis, especially in the scientific evaluation of drugs. We have a strong scientific background and many years of experience working hand-in-hand with pharma – developing drugs and supervising M&A activities. Together with our team, we have perfectionated the prediction of the clinical trial readouts over the years.
Publicly traded biotechnology companies of which the SV Inflections FCP-RAIF held shares during the announcement of key clinical data readouts. In all cases, urgently needed novel therapies advanced a considerable step towards alleviating the suffering of patients. *
* The Content of these investments in the past is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
Can we provide more information? Please don’t hesitate to get in touch.